Effect of SGLT-2 Inhibitors on Non-alcoholic Fatty Liver Disease among Patients with Type 2 Diabetes Mellitus: Systematic Review with Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials
Open Access
- 15 May 2021
- journal article
- review article
- Published by Oman Medical Journal in Oman Medical Journal
- Vol. 36 (3), e273
- https://doi.org/10.5001/omj.2021.62
Abstract
Objectives: Non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) is a common problem associated with obesity and type 2 diabetes mellitus (T2DM). There have been anecdotal reports of the efficacy of sodium-glucose cotransporter 2 inhibitors (SGLT2Is) in improving liver function parameters in those with concomitant T2DM and NAFLD/NASH. We sought to systematically evaluate the evidence of SGLT2Is in improving liver function parameters in T2DM patients with NAFLD, considering the risks of random error based on trial sequential analysis (TSA). We also performed a meta-analysis based on a random-effects model. Methods: A systematic literature search was performed using the Medline, Cochrane, and Embase databases from inception to 20 October 2018. Primary outcome for meta-analyses was the changes in hepatic enzyme levels (alanine transaminase, aspartate transaminase, and gamma-glutamyl transpeptidase). We also performed a meta-analysis on changes in insulin resistance, glycemic, and lipid parameters using SGLT2Is as a secondary objective. Results: Eight eligible randomized controlled studies were eligible for analysis. Meta-analysis showed the efficacy of two SLT2Is, dapagliflozin, and canagliflozin in reducing these enzymes level. TSA showed that canagliflozin significantly reduced the gamma-glutamyl transpeptidase level by weighted mean difference (-5.474, 95% confidence interval (CI): -6.289–-4.659) compared to others comparators, and the evidence is conclusive. Dapagliflozin also had a statistically significant reduction in glycated hemoglobin, which is a parameter of glycemic control and homeostatic model assessment for insulin sensitivity (HOMA-IR), which is a parameter of insulin sensitivity by a weight mean difference, -0.732 (95% CI: -1.087–-0.378) and -0.804 (95% CI: -1.336–0.272), respectively. Conclusions: This study indicated that canagliflozin effectively improves liver function parameters among patients with diabetes, while dapagliflozin is more effective in improving glycemic indices and insulin sensitivity.Keywords
This publication has 37 references indexed in Scilit:
- Therapies in non‐alcoholic steatohepatitis (NASH)Liver International, 2017
- Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non‐alcoholic fatty liver disease and type 2 diabetes mellitusHepatology Research, 2016
- Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Common Pathophysiologic MechanismsCurrent Diabetes Reports, 2015
- Sitagliptin as a Novel Treatment Agent for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes MellitusHepato-Gastroenterology, 2011
- Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 yearsGut, 2010
- Clinical trial: pilot study of metformin for the treatment of non‐alcoholic steatohepatitisAlimentary Pharmacology & Therapeutics, 2008
- Non-alcoholic fatty liver disease and hepatitis C infection.2006
- Review article: non‐alcoholic fatty liver disease and hepatitis C – risk factors and clinical implicationsAlimentary Pharmacology & Therapeutics, 2005
- Pathologic features associated with fibrosis in nonalcoholic fatty liver diseaseHuman Pathology, 2004
- A pilot study of pioglitazone treatment for nonalcoholic steatohepatitisHepatology, 2004